1. 214-OR: Effects of Polyphenols on Cholesterol Efflux and Insulin Secretion in MIN6 Cells
- Author
-
KOTA MATSUKI, YUKI KIMURA, KOKI MATSUMURA, JUTARO TANABE, HIROSHI MURAKAMI, and MAKOTO DAIMON
- Subjects
Endocrinology, Diabetes and Metabolism ,Internal Medicine - Abstract
Background: Diabetic dyslipidemia is characterized by elevated levels of triglyceride-rich lipoproteins and reduced levels of HDL-cholesterol (HDL-C) . Low levels of HDL-C are associated with an increased risk of atherosclerotic cardiovascular disease, because HDL protects against atherosclerosis through multiple mechanisms include removal of excess cholesterol from macrophages. HDL can also influence cholesterol homeostasis in pancreatic β-cell. It is noteworthy that absence of ATP-binding cassette transporter A1 (ABCA1) , which is a cellular cholesterol transporter and regulates islet cholesterol efflux, results in islet cholesterol overload and impaired insulin release in mice. We examined the associations of cholesterol efflux and insulin secretion in MIN6 cells with polyphenols that is reported to increase cholesterol efflux. Methods: Murine MIN6 cells were labeled with 3H-cholesterol and incubated with ApoA1 (μg/ml) or HDL (25 μg/ml) for 24 hours. The percentage cholesterol efflux was calculated by dividing the media-derived radioactivity by the sum of the radioactivity in the media and the cells. The effect of polyphenols on the cholesterol efflux was studied, adding that into the medium before the analysis of the cholesterol efflux. Insulin secretion was assessed by ELISA as the concentration of insulin in the culture medium. The mRNA expression of ABCA1 and ABCG1 were determined by real-time Quantitative RT-PCR. Results: Under the existence of polyphenols (isorhamnetin) , the ApoA1 or HDL-mediated cholesterol efflux had significantly increased by 1.4% or 1.8%, respectively (n=4, p Conclusion: These data suggest that isorhamnetin increases cholesterol efflux and insulin secretion in MIN6 cells. Isorhamnetin could be the interesting candidate to investigate the new treatment for patients with diabetes mellitus. Disclosure K.Matsuki: None. Y.Kimura: None. K.Matsumura: None. J.Tanabe: None. H.Murakami: None. M.Daimon: None. Funding JSPS KAKENHI Grant Number 20K11549
- Published
- 2022
- Full Text
- View/download PDF